Overview

• Researchers secured a $1 million Part the Cloud grant from the Alzheimer’s Association to support the first human trial of a virus-like particle vaccine targeting pathological tau.
• Vaccine production is underway at TheraVac Biologics under FDA good manufacturing practice standards to meet trial requirements.
• The Phase 1a/1b double-blind study will randomize half of the participants to receive the active pT181-conjugated vaccine and half a placebo.
• Safety and tolerability are the primary endpoints with immunogenicity assessed by measuring anti-tau antibody responses.
• Enrollment is set to begin in early 2026 at the UNM Center for Memory & Aging under the direction of Janice Knoefel.